NKG2D fine-tunes the local inflammatory response in colorectal cancer
Identified with Open Access button
AffiliationDepartment of Life Sciences, Imperial College London, London SW7 2BX, UK
MetadataShow full item record
AbstractTreating colorectal cancer (CRC) is a major challenge due to the heterogeneous immunological, clinical and pathological landscapes. Immunotherapy has so far only proven effective in a very limited subgroup of CRC patients. To better define the immune landscape, we examined the immune gene expression profile in various subsets of CRC patients and used a mouse model of intestinal tumors to dissect immune functions. We found that the NK cell receptor, natural-killer group 2 member D (NKG2D, encoded by KLRK1) and NKG2D ligand gene expression is elevated in the most immunogenic subset of CRC patients. High level of KLRK1 positively correlated with the mRNA expression of IFNG and associated with a poor survival of CRC patients. We further show that NKG2D deficiency in the Apcmin/+ mouse model of intestinal tumorigenesis led to reduced intratumoral IFNγ production, reduced tumorigenesis and enhanced survival, suggesting that the high levels of IFNγ observed in the tumors of CRC patients may be a consequence of NKG2D engagement. The mechanisms governing the contribution of NKG2D to CRC progression highlighted in this study will fuel discussions about (i) the benefit of targeting NKG2D in CRC patients and (ii) the need to define the predictive value of NKG2D and NKG2D ligand expression across tumor types.
CitationCurio S, Lin W, Bromley C, McGovern J, Triulzi C, Jonsson G, et al. NKG2D Fine-Tunes the Local Inflammatory Response in Colorectal Cancer. Cancers (Basel). 2023 Mar 16;15(6). PubMed PMID: 36980678. Pubmed Central PMCID: PMC10046042. Epub 2023/03/30. eng.
- Peripheral Foxp3+ regulatory T cells and natural killer group 2, member D expression levels in natural killer cells of patients with colorectal cancer.
- Authors: Shen Y, Wang Q, Qi Y, Cui B, Zhang Z, Su J, Liu X, Lu C, Ye H, Ju Y, Lu Z
- Issue date: 2014 Aug
- Natural killer NKG2A and NKG2D in patients with colorectal cancer.
- Authors: Meckawy GR, Mohamed AM, Zaki WK, Khattab MA, Amin MM, ElDeeb MA, El-Najjar MR, Safwat NA
- Issue date: 2019 Apr
- Possible association of decreased NKG2D expression levels and suppression of the activity of natural killer cells in patients with colorectal cancer.
- Authors: Shen Y, Lu C, Tian W, Wang L, Cui B, Jiao Y, Ma C, Ju Y, Zhu L, Shao C, Liu X, Wang J, Zhang B, Lu Z
- Issue date: 2012 Apr
- Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D.
- Authors: Sayitoglu EC, Georgoudaki AM, Chrobok M, Ozkazanc D, Josey BJ, Arif M, Kusser K, Hartman M, Chinn TM, Potens R, Pamukcu C, Krueger R, Zhang C, Mardinoglu A, Alici E, Temple HT, Sutlu T, Duru AD
- Issue date: 2020
- NKG2D engagement of colorectal cancer-specific T cells strengthens TCR-mediated antigen stimulation and elicits TCR independent anti-tumor activity.
- Authors: Maccalli C, Pende D, Castelli C, Mingari MC, Robbins PF, Parmiani G
- Issue date: 2003 Jul